A great, fat opportunity for big pharma


The next great opportunity for pharmaceutical companies is in a disease many people don't know about.

Investors and industry observers should expect to hear a lot about nonalcoholic steatepathitis, or delicacy, in the coming year. Treating this severe form of fatty liver disease is a massive business opportunity, but investors will need patience for promising to develop profits.

Nearly …

Source link